What the Drone Industry’s Thankful for in 2020

Both pilots and companies are navigating a thin line between security and innovation. Host Grant Guillot talks with leaders, influencers, and experts across the drone industry to guide us through the complex web of technology and policy in the United States.

 

Even in a chaotic year like 2020, there are things to be thankful for – and “Drones in America” host Grant Guillot said there are plenty of reasons to be grateful if you’re a player in the commercial drone industry.

Many of those reasons stemmed from necessity and an accelerated pace of innovation in response to the spread of the novel coronavirus and the ensuing COVID-19 pandemic.

For example, drone delivery has been thrust into the spotlight – though it perhaps didn’t materialize in the way that many expected it to during this turbulent year thanks to essential worker distinctions and more, the conversation has still accelerated.

“People who had a tendency to fear drones and not really understand what they can be used for began to really see the potential in drone deliveries,” Guillot said.

Drones also saw more widespread use in the energy and oil and gas industries, which Guillot said are primed to exit the COVID-19 pandemic and become even greater end-users of drones.

“I think it’s only a matter of time before we see a lot more use of drones in the oil and gas industry and other industries that were kind of hampered or slowed down because of COVID,” he said.

Catch up on previous episodes of Drones In America!

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More